KAMADA » INVESTORS

INVESTMENT HIGHLIGHTS

LATEST NEWS

Kamada announced the extension of an ongoing investigator initiated, proof-of-concept study evaluating the potential benefit of the Company’s liquid Alpha-1 Antitrypsin (AAT) on liver preservation and transplant rejection prevention.

Sep. 5, 2018

Kamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation.

Kamada Provides Updated Full-Year 2018 Revenue Guidance

Aug. 29, 2018

As result of the recent labor strike part of 2018 shipments are likely to be delayed to early 2019 Subsequent update and full-year 2019 revenue guidance to be provided later this year.

More News

FINANCIAL REPORTS

Q1 / 2018 Financial Report

Jul. 15, 2018

XBRL Annual Reports 2017

Dec. 31, 2017

Annual Report 2017

Dec. 30, 2017

More Reports

STOCK QUOTE

NASDAQ

KMDA:$0
Change:0.00%
Date & Time:
For more information: KAMADA on NASDAQ website

TASE

Share price                                             Daily volume(NIS)                

Click here for more information 

 Convertible bond                                  Daily volume(NIS)

Click here for more information

 For more information: KAMADA on Tel- Aviv Stock Exchange website

CORPORATE GOVERNANCE

Please click "Read more" to view Kamada's Corporate Governance items.

Read more

IR CONTACT & FAQ

Chaime Orlev,
CFO
ir@kamada.com

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

 

Read more